DURECT (NASDAQ:DRRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX) in a research report sent to investors on Friday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating on shares of DURECT in a report on Thursday, November 14th.

DURECT Stock Down 3.7 %

DURECT stock opened at $0.76 on Friday. The company has a 50 day moving average of $0.84 and a 200-day moving average of $1.17. DURECT has a twelve month low of $0.70 and a twelve month high of $1.88. The stock has a market capitalization of $23.59 million, a PE ratio of -1.25 and a beta of 0.91.

Institutional Trading of DURECT

An institutional investor recently raised its position in DURECT stock. Geode Capital Management LLC boosted its holdings in DURECT Co. (NASDAQ:DRRX) by 4.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 319,905 shares of the specialty pharmaceutical company’s stock after purchasing an additional 14,658 shares during the period. Geode Capital Management LLC owned about 1.03% of DURECT worth $429,000 as of its most recent filing with the Securities and Exchange Commission. 28.03% of the stock is currently owned by institutional investors and hedge funds.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.